

1 **TITLE**

2 **The co-occurrence of genetic variants in the *TYR* and *OCA2* genes confers**
3 **susceptibility to albinism**

4

5 **AUTHOR LIST & AFFILIATIONS**

6 David J. Green¹, Vincent Michaud^{2,3}, Eulalie Lasseaux², Claudio Plaisant², UK
7 Biobank Eye and Vision Consortium, Tomas Fitzgerald⁴, Ewan Birney⁴, Graeme C.
8 Black^{1,5,#}, Benoît Arveiler^{2,3,#}, Panagiotis I. Sergouniotis^{1,4,5,6}

9

10 ¹ Division of Evolution, Infection and Genomics, School of Biological Sciences,
11 Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

12

13 ² Department of Medical Genetics, University Hospital of Bordeaux, Bordeaux,
14 France.

15

16 ³ INSERM U1211, Rare Diseases, Genetics and Metabolism, University of
17 Bordeaux, Bordeaux, France.

18

19 ⁴ European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-
20 EBI), Wellcome Genome Campus, Cambridge, UK.

21

22 ⁵ Manchester Centre for Genomic Medicine, Saint Mary's Hospital, Manchester
23 University NHS Foundation Trust, Manchester, UK.

24

25 ⁶ Manchester Royal Eye Hospital, Manchester University NHS Foundation Trust,
26 Manchester, UK.

27

28

29 # These authors contributed equally: Graeme C. Black, Benoît Arveiler

30

31 Correspondence to

32 Panagiotis I. Sergouniotis (panagiotis.sergouniotis@manchester.ac.uk).

33

34 **ABSTRACT**

35

36 Although rare genetic conditions are mostly caused by DNA sequence alterations
37 that functionally disrupt individual genes, large-scale studies using genome
38 sequencing have started to unmask additional complexity. Understanding how
39 combinations of variants in different genes shape human phenotypes is expected to
40 provide important insights into the clinical and genetic heterogeneity of rare
41 disorders. We used albinism, an archetypal rare condition associated with
42 hypopigmentation, as an exemplar for the study of genetic interactions. We analysed
43 data from the Genomics England 100,000 Genomes Project alongside a cohort of
44 1,120 individuals with albinism, and investigated the effect of dual heterozygosity for
45 the combination of two established albinism-related variants: *TYR*:c.1205G>A
46 (p.Arg402Gln) [rs1126809] and *OCA2*:c.1327G>A (p.Val443Ile) [rs74653330]. As
47 each of these changes alone is insufficient to cause disease when present in the
48 heterozygous state, we sought evidence of synergistic effects. We found that, when
49 both variants are present, the probability of receiving a diagnosis of albinism is
50 significantly increased (odds ratio 12.8; 95% confidence interval 6.0 – 24.7; p-value
51 2.1×10^{-8}). Further analyses in an independent cohort, the UK Biobank, supported
52 this finding and highlighted that heterozygosity for the *TYR*:c.1205G>A and
53 *OCA2*:c.1327G>A variant combination is associated with statistically significant
54 alterations in visual acuity and central retinal thickness (traits that are considered
55 albinism endophenotypes). The approach discussed in this report opens up new
56 avenues for the investigation of oligogenic patterns in apparently Mendelian
57 disorders.

58

59 **KEYWORDS:** epistasis, digenic, oligogenic, bi-locus, genetic interaction

60 **MAIN TEXT**

61 **INTRODUCTION**

62

63 An individual affected by a condition that appears to segregate as a Mendelian trait,
64 would be expected to carry large-effect genetic variation in a single gene/locus.

65 However, for a significant proportion of affected probands, single-gene-centric
66 genomic analyses fail to identify a clear genetic diagnosis.¹⁻⁶ Although this diagnostic
67 and knowledge gap is, to a degree, due to imperfect phenotyping, sequencing or
68 annotation, other factors may be contributing. There is for example growing evidence
69 supporting the hypothesis that many apparently Mendelian phenotypes are caused
70 by the interaction of multiple variants in more than one locus.⁷⁻¹¹ Uncovering such
71 genetic interactions has the potential to provide insights not only into disease
72 mechanisms and diagnostics but also into phenomena like incomplete penetrance
73 and variable expressivity.¹²⁻¹⁴

74

75 There are many patterns through which genetic changes in more than one gene can
76 synergistically shape a phenotype. A simple scenario, would involve two
77 heterozygous variants in two distinct loci cooperating to mediate disease (when each
78 individual variant in isolation fails to explain the clinical presentation). Only a small
79 number of cases with this specific form of digenic inheritance have been described¹⁵⁻
80 ¹⁷, the majority detected through qualitative approaches involving variant segregation
81 analyses in a small number of families. In these cases, interaction-based models
82 have generally been used to provide a post hoc explanation of the observed
83 phenomena. By contrast, we describe a quantitative, case-control approach that
84 allows obtaining statistical evidence of digenic patterns. We focused on specific
85 genotypes in the *TYR* and *OCA2* genes; biallelic variants in each of these two genes

86 are associated with albinism, a clinically and genetically heterogeneous group of
87 conditions characterised by reduced levels of melanin pigment. Key features of
88 albinism include visual abnormalities and under-development of the central retina
89 (*i.e.* the fovea); skin and/or hair hypopigmentation may also be present.¹⁸ Building on
90 recent work¹⁹⁻²², we aimed to advance our understanding of the genetic complexity
91 of this rare disorder.

92

93

94 **RESULTS & DISCUSSION**

95

96 A cohort of 1,015 people with albinism underwent testing of ≤ 19 albinism-related
97 genes; these individuals were not known to be related and had predominantly
98 European-like ancestries (Supplementary Data 1). A further 105 probands with
99 albinism were identified in the Genomics England 100,000 Genomes Project
100 dataset.²³ A “control” cohort of 29,451 unrelated individuals that had no recorded
101 diagnosis or features of albinism was also identified in this resource (Fig.1,
102 Supplementary Table 1, Methods).

103




Figure 1. Outline of the case-control study design.

A case-control analysis was performed to gain insights into the role of genotypes involving dual heterozygosity for *TYR*:c.1205G>A (p.Arg402Gln) [rs1126809] and *OCA2*:c.1327G>A (p.Val443Ile) [rs74653330] in albinism. These two missense changes were selected as they are the commonest albinism-related variants in European-like populations.

The majority of participants in the “case” cohort (1,015/1,120) were identified through the database of the University Hospital of Bordeaux Molecular Genetics Laboratory, France. All these probands had at least one key ocular feature of albinism, *i.e.* nystagmus or prominent foveal hypoplasia (see Methods). The remaining 105/1,120 cases were identified through the Genomics England 100,000 Genomes Project dataset and had a diagnosis of albinism or partial/ocular albinism. The “control” cohort included 29,451 unrelated individuals from the Genomics England 100,000 Genomes Project dataset, none of whom had a recorded diagnosis of albinism.

To reduce the likelihood of obtaining spurious signals due to population stratification effects or due to the presence of albinism-related variants other than the two studied changes, we focused only on individuals who: (i) were projected to have European-like ancestries; (ii) did not have a genotype in keeping with a molecular diagnosis of albinism; (iii) were not heterozygous for a pathogenic or a likely pathogenic variant in *TYR* or *OCA2* (excluding *TYR*:c.1205G>A and *OCA2*:c.1327G>A). The following two covariates were used: sex and number of common albinism-associated alleles, *i.e.* DNA sequence alterations in the genomic locations corresponding to *TYR*:c.-301C>T [rs4547091] and *TYR*:c.575C>A (p.Ser192Tyr) [rs1042602]. These two variants have been previously shown to modify the effect of *TYR*:c.1205G>A which is a common missense change that can act as a “hypomorphic” variant.¹⁹⁻²¹

To assess the robustness of the findings we performed additional analyses in subsets of the cohort. Validation studies in an independent cohort (UK Biobank) were also conducted.

100K_GP, Genomics England 100,000 Genomes Project; het, heterozygous; UKB, UK Biobank.
TYR and *OCA2* variant numbering was based on the transcripts with the following identifiers:
NM_000372.5/ENST00000263321.6. and NM_000275.3/ENST00000354638.8.

105

106 Searching for genetic elements underlying digenic traits may be carried out at the
107 level of genes, genotypes or DNA variants. It is noted that a given pair of DNA
108 variants comprises up to nine pairs of genotypes while a given gene may contain a
109 large number of variants. Each of these search strategies has inherent advantages
110 and pitfalls.²⁴ We opted for a genotype-based approach that offers a high level of
111 precision and is more likely to provide insights that can be used for clinical genome
112 interpretation.

113

114 Our genotype-based analysis focused on two prevalent albinism-related changes,
115 *TYR*:c.1205G>A (p.Arg402Gln) [rs1126809] and *OCA2*:c.1327G>A (p.Val443Ile)
116 [rs74653330]. We hypothesised that when these two missense variants are both
117 present in the heterozygous state (“dual heterozygosity”), their interaction is driving
118 the pathology observed in albinism. Notably, both these changes have been shown
119 to reduce the activity of their respective protein products *in vitro*.²⁵⁻²⁹ Further,
120 previous studies have pointed to a functional interaction between the *TYR* and *OCA2*
121 proteins: the latter has a role in the pH regulation of the melanosome which, in turn,

122 can affect the catalytic activity of the former (*i.e.* tyrosinase, the rate-limiting enzyme
123 for the synthesis of melanin in the melanosomes of retinal pigment epithelia and
124 melanocytes).^{18,30} Both *TYR*:c.1205G>A and *OCA2*:c.1327G>A have been
125 implicated in albinism when *in trans* with pathogenic changes in the same gene.^{21,31}
126 Also, multiple associations have been recorded for these two variants including with
127 skin/hair pigmentation and skin cancer.³² It is noted that these two changes were
128 chosen as they are the two commonest albinism-related variants in populations of
129 European-like ancestries, a feature that can help mitigate potential issues with
130 statistical power. It is also highlighted that the minor allele frequencies of the
131 *TYR*:c.1205G>A and *OCA2*:c.1327G>A changes in European populations are 27%
132 and 0.3% respectively (Non-Finnish European subset of the Genome Aggregation
133 Database [gnomAD] v2.1.1).³³ The particularly common *TYR*:c.1205G>A change
134 has been associated with incomplete penetrance (and variable expressivity), and
135 previous studies have pointed to the potential for other *TYR* variants to modify its
136 effect.^{19-21,25,34-36}

137


138 We used Firth regression analysis^{37,38} to study how dual heterozygosity for
139 *TYR*:c.1205G>A and *OCA2*:c.1327G>A affects the probability of receiving a
140 diagnosis of albinism (“risk of albinism”). This logistic regression approach has been
141 designed to handle small, imbalanced datasets (which are common in studies of rare
142 conditions) and allows for adjustment of key covariates (which is not possible in
143 contingency table methods) (Fig.1). To increase the genetic similarity³⁹ between the
144 compared cohorts (cases and controls) and to reduce the impact of albinism-related
145 variants other than the two studied changes (*TYR*:c.1205G>A and
146 *OCA2*:c.1327G>A), we excluded from our analysis individuals that: (i) did not have

147 European-like ancestries, (ii) were found to have genotypes in keeping with a
148 molecular diagnosis of albinism, (iii) carried pathogenic or likely pathogenic variants
149 in the *TYR* or *OCA2* gene (with the exception of *TYR*:c.1205G>A and
150 *OCA2*:c.1327G>A). The resulting case and control cohorts included 204 and 20,350
151 individuals respectively. These were used to perform case-control comparisons
152 between the following genotype groups:

- 153 • *group A* (reference group): homozygous for *TYR*:c.1205= and *OCA2*:c.1327=
- 154 • *group B* (single *TYR* heterozygote group): heterozygous for *TYR*:c.1205G>A and
155 homozygous for *OCA2*:c.1327=.
- 156 • *group C* (single *OCA2* heterozygote group): homozygous for *TYR*:c.1205G= and
157 heterozygous for *OCA2*:c.1327G>A.
- 158 • *group D* (dual heterozygote group): heterozygous for the *TYR*:c.1205G>A and
159 *OCA2*:c.1327G>A variant combination.

160 These groups correspond to different levels of dysfunction of the *TYR* and *OCA2*
161 molecules and the findings of the regression analysis revealed a synergistic
162 potentiation of the changes at the two loci (Fig.2, Supplementary Fig.1a and
163 Supplementary Table 2). The point estimate for the odds of receiving a diagnosis of
164 albinism in individuals who are heterozygous for the *TYR*:c.1205G>A and
165 *OCA2*:c.1327G>A variant combination was 12.8 (the 95% confidence interval was
166 6.0 – 24.7 and the p-value was 2.1×10^{-8}).

167



168

169 To increase confidence in these observations, we performed additional analyses in
 170 an independent cohort, the UK Biobank.⁴⁰ We found that UK Biobank volunteers who
 171 were heterozygous for the *TYR*:c.1205G>A and *OCA2*:c.1327G>A variant
 172 combination had not only a higher chance of receiving a diagnosis of albinism
 173 (OR>6.9, p-value=0.0004) but also had, on average, slightly worse visual acuity and

174 marginally thicker central retina (the respective Kruskal-Wallis p-values were 1.4 x
175 10^{-3} and 8.2×10^{-4} ; Fig.3 and Supplementary Tables 3-6). It is noted that visual
176 acuity and central retinal thickness are quantitative endophenotypes of albinism and
177 these findings suggest that the studied *TYR/OCA2* variant combination is both
178 contributing to the genetic architecture of albinism and having a role in the
179 development of the visual system in individuals from the general population.
180




Figure 3. The combination of the *TYR*:c.1205G>A (p.Arg402Gln) and *OCA2*:c.1327G>A (p.Val443Ile) variants in a dual heterozygous state is associated with (a) a higher probability of receiving an albinism diagnosis (*i.e.* a higher risk of albinism), (b) lower visual acuity and (c) increased central retinal thickness in UK Biobank participants.

The following genotype groups were studied:

- **group A** (reference group): homozygous for *TYR*:c.1205= and *OCA2*:c.1327=
- **group B** (single *TYR* heterozygote group): heterozygous for *TYR*:c.1205G>A and homozygous for *OCA2*:c.1327=
- **group C** (single *OCA2* heterozygote group): homozygous for *TYR*:c.1205G= and heterozygous for *OCA2*:c.1327G>A
- **group D** (dual heterozygote group): heterozygous for the *TYR*:c.1205G>A and *OCA2*:c.1327G>A variant combination.

It is noted that individuals with albinism tend to have reduced visual acuity (*i.e.* higher LogMAR value than 0.2) and increased central retinal thickness (due to underdevelopment of the fovea). More details on the utilised approach can be found in the Methods and in Supplementary Fig.2 and 3. Further information including numerical data can be found in Supplementary Tables 3-6.

181

182 We provide evidence that the *TYR*:c.1205G>A and *OCA2*:c.1327G>A changes

183 appear to have a joint effect when each is encountered in the heterozygous state.

184 However, the interpretation of this variant combination in clinical diagnostic settings
185 should be approached cautiously. Although the detected effect size (odds ratio) is
186 significant, it would be more in keeping with a predisposing⁴¹ rather than a
187 pathogenic⁴² genotype. Further, while it is tempting to view our observations as an
188 example of a digenic pattern, this would have reductionist connotations; interactions
189 are ubiquitous in nature and we expect that increased sample sizes will elucidate
190 longer “chains” of interconnected genetic variation. It is thus plausible that the effect
191 size of the studied genotype will increase when further genetic changes that impact
192 on tyrosinase function or melanosome pH are added to the model. Indeed,
193 observations in the presented data already point to this possibility (Supplementary
194 Fig.3; Supplementary Data 2 and 3).

195

196 One limitation of this study is our inability to match stringently the albinism cases with
197 the unaffected controls, especially in terms of genetic background.⁴³ Although recent
198 ancestry was considered, our analysis was imperfect as it was not possible to
199 reliably assign genetic ancestry to most albinism cases. We used a combination of
200 orthogonal approaches to evaluate the robustness and generalisability of our
201 findings. First, we used 35 presumed neutral single-nucleotide variants to calculate
202 the genomic inflation factor lambda (λ_{GC})^{44,45}; the λ_{median} was found to be 1.04, in
203 keeping with limited confounding by ancestry (Supplementary Table 7).

204 Subsequently, we performed a targeted secondary analysis using only Genomics
205 England 100,000 Genomes Project data which allowed us to study case and control
206 groups of high genetic similarity. The results supported our key findings and
207 increased confidence in the validity of the detected associations (Supplementary
208 Fig.1b and Supplementary Table 8). Another potential caveat is that the detected

209 signal in dual heterozygotes for *TYR*:c.1205G>A and *OCA2*:c.1327G>A could, to a
210 degree, be driven by undetected pathogenic variation in either *TYR* or *OCA2*. This
211 cannot be excluded despite the fact that medical-grade genetic analyses were
212 undertaken. It can be argued however that significant confounding is unlikely
213 especially given that the effect of dual heterozygosity for *TYR*:c.1205G>A and
214 *OCA2*:c.1327G>A appears to be consistently greater than that of genotypes
215 involving heterozygosity for either *TYR*:c.1205G>A or *OCA2*:c.1327G>A alone
216 (Supplementary Tables 2, 3, 8 and 9). Nonetheless, statistically significant results
217 were also obtained for individuals carrying the *OCA2*:c.1327G>A change in
218 heterozygous state (without *TYR*:c.1205G>A) and future studies will provide further
219 insights into the extent to which this change alone drives the observed signal.

220

221 In conclusion, we have shown that dual heterozygosity for a *TYR* and an *OCA2*
222 variant confers susceptibility to albinism. Shedding light into this and other variant
223 interactions is expected to increase our understanding of the pathways and cellular
224 processes affected in albinism. Notably, the concepts discussed herein are likely to
225 be relevant to other rare disorders, and systems-based approaches using biological
226 modules are expected to narrow the molecular diagnostic gap. Future work will focus
227 on increasing sample sizes, embracing more diverse populations and searching for
228 high-order interactions by considering more than two variants at a time.

229

230 **METHODS**

231

232 **Cohort characteristics and genotyping**

233 *University Hospital of Bordeaux albinism cohort*

234 Individuals with albinism were identified through the database of the University Hospital of Bordeaux

235 Molecular Genetics Laboratory, France. This is a national reference laboratory that has been

236 performing genetic testing for albinism since 2003 and has been receiving samples from individuals

237 predominantly based in France (or French-administered overseas territories).

238

239 Information on the dermatological and ophthalmological phenotypes was available for all affected

240 individuals. The relevant clinical data were assessed independently by two clinicians with experience

241 in the field of albinism and only cases with a consensus clinical impression of albinism were included.

242 It is noted that and each of these cases had at least one of the key ocular features of albinism, *i.e.*

243 infantile nystagmus or absence of a foveal pit (prominent foveal hypoplasia) (Supplementary Table

244 10). No pre-screening based on genotype was undertaken other than selecting individuals in whom

245 position c.-301 of *TYR* was sequenced. Only individuals who were not knowingly related were

246 included.

247

248 Genetic testing, bioinformatic analyses, and variant interpretation were performed as previously

249 described.^{20,21} Briefly, most participants had gene-panel testing of ≤ 19 genes associated with albinism

250 (*C10ORF11*, *GPR143*, *HPS 1* to 10, *LYST*, *OCA2*, *SLC38A8*, *SLC24A5*, *SLC45A2*, *TYR*, *TYRP1*)

251 using IonTorrent platforms. High-resolution array-CGH (comparative genomic hybridization) was used

252 to detect copy number variants in these genes. All genetic changes of interest were confirmed with an

253 alternative method (e.g. Sanger sequencing or quantitative PCR). Clinical interpretation of variants

254 was performed using criteria consistent with the 2015 American College of Medical Genetics and

255 Genomics (ACMG) best practice guidelines.⁴² It is noted that genetic findings in this cohort have been

256 partly reported in previous publications from our group^{19,22} and that comprehensive genomic testing

257 (including single-nucleotide variant and copy number variant analysis involving the aforementioned 19

258 albinism-related genes) was performed in all cases that remained unsolved.

259

260 Due to the limited number of genomic loci screened in this cohort, it was not possible to reliably

261 assess genetic ancestry and to “objectively” assign individuals to genetic ancestry groups. Attempting

262 to mitigate this, we processed available data on self-identified ethnicity that were collected through
263 questionnaires. Responses were inspected and stratification into five broad continental groups
264 (European, African, Admixed American, East Asian, South Asian) was performed.
265
266
267
268 *Genomics England 100,000 Genomes Project cohort*

269 Clinical and genomic data from the Genomics England 100,000 Genomes Project were accessed
270 through a secure Research Environment that is available to registered users. This dataset was
271 collected as part of a national genome sequencing initiative.⁴⁶ Enrolment was coordinated by
272 Genomics England Limited, and participants were recruited mainly at National Health Service (NHS)
273 Hospitals in the UK.²³ Clinical information was recorded in Human Phenotype Ontology (HPO)⁴⁷ terms
274 and International Classification of Diseases (ICD) codes. Genome sequencing was performed in DNA
275 samples from $\geq 78,195$ individuals using Illumina HiSeq X systems (150 base-pair paired-end format).
276 Reads were aligned using the iSAAC Aligner v03.16.02.19 and small variants were called using
277 Starling v2.4.7.⁴⁸ Structural variants and long indel (>50bp) calling was performed with Manta v0.28.0,
278 and copy number variants (CNVs) were called with Canvas v1.3.1.^{49,50} Aggregation of single-sample
279 gVCFs was performed using the Illumina software gVCF genotyper v2019.02.29;
280 normalisation/decomposition was implemented by vt v0.57721⁵¹. The multi-sample VCF was then split
281 into 1,371 roughly equal chunks to allow faster processing and the loci of interest were queried using
282 bcftools v1.9⁵² (see <https://research-help.genomicsengland.co.uk/display/GERE/> for further
283 information). Only variants that passed standard quality control criteria were processed (including the
284 criteria discussed in https://re-docs.genomicsengland.co.uk/site_gc/ and criteria analogous to those
285 outlined in https://re-docs.genomicsengland.co.uk/somatic_sv/#note-on-variant-calling). In addition,
286 we filtered out genotypes with: genotype score <20; read depth <10; allele balance <0.2 and >0.8 for
287 heterozygotes; allele balance >0.1 or <0.9 for homozygotes (reference and alternate, respectively).
288 Genomic annotation was performed using Ensembl VEP⁵³. Variants with a “total” minor allele
289 frequency (MAF) <1% in the Genome Aggregation Database (gnomAD v2.1.1)³³ and a “disease-
290 causing” (DM) label in the Human Gene Mutation Database (HGMD) v2021.2⁵⁴ were flagged (and are
291 hitherto referred to as “HGMD-listed variants”). In depth manual curation of all detected rare (*i.e.*
292 MAF < 1%) variants in *TYR* and *OCA2* was undertaken and these changes were classified according
293 to the 2015 American College of Medical Genetics and Genomics (ACMG) best practice guidelines.⁴²

294
295 Ancestry inference was performed in the Genomics England 100,000 Genomes Project cohort using
296 principal component analysis. Data from the 1000 genomes project (phase 3) dataset were used and
297 five broad super-populations were projected (European, African, Admixed American, East Asian,
298 South Asian) (further information on this can be found online at [https://research-
299 help.genomicsengland.co.uk/display/GERE/Ancestry+inference](https://research-help.genomicsengland.co.uk/display/GERE/Ancestry+inference)).
300
301 We focused on a pre-determined subset of the Genomics England 100,000 Genomes Project dataset
302 that includes only unrelated probands (n=29,556). Of these, 105 had a diagnosis of albinism, *i.e.* the
303 ICD-10 term “Albinism” [E70.3] and/or the HPO terms “Albinism” [HP:0001022], “Partial albinism”
304 [HP:0007443] or “Ocular albinism” [HP:0001107] were assigned (Supplementary Table 10). Together
305 with the University Hospital of Bordeaux cases, these 105 probands formed the “case” cohort. The
306 remaining 29,451 probands had no recorded diagnosis or phenotypic features of albinism and formed
307 the “control” cohort. We note that comprehensive ophthalmic phenotyping was not routinely
308 undertaken in Genomics England 100,000 Genomes Project participants. We cannot therefore be
309 certain that a small number of individuals with mild/subclinical forms of albinism are not included in
310 the control cohort.

311

312

313 **Case-control analysis to estimate the probability of an albinism diagnosis**

314 The effect of dual heterozygosity for *TYR*:c.1205G>A (p.Arg402Gln) [rs1126809] and
315 *OCA2*:c.1327G>A (p.Val443Ile) [rs74653330] on the probability of receiving a diagnosis of albinism
316 (*i.e.* the albinism risk) was estimated using data from the University Hospital of Bordeaux albinism
317 cohort and the Genomics England 100,000 Genomes Project dataset. A case-control analysis of a
318 binary trait (presence/absence of albinism) was conducted assuming a recessive model. Logistic
319 regression using the Firth bias reduction method^{37,38} was utilised (as implemented in “logistf” R
320 package). The following parameters were set:

- 321 • inclusion criteria: the analysis was conducted only on study subjects who: (i) were projected to
322 have European-like ancestries, (ii) were not found to have genotypes in keeping with a molecular
323 diagnosis of albinism, (iii) carried no pathogenic or likely pathogenic variants in the *TYR* or *OCA2*
324 gene (with the exception of the two studied changes *TYR*:c.1205G>A and *OCA2*:c.1327G>A).
- 325 • covariates: sex; number of common albinism-associated alleles (see relevant sub-section below).

326

327 *Ancestry*: To increase the genetic similarity between the studied case and control cohorts, we focused
328 on individuals who were likely to fall within the same broad ancestral group. It is highlighted though
329 that the utilised approach was imperfect as it was not possible to objectively determine genetic
330 ancestry in individuals from the University Hospital of Bordeaux albinism cohort (as mentioned above,
331 self-identified ethnicity was instead used as a surrogate). Confounding by ancestry (*i.e.* population
332 stratification) is therefore a possibility.³⁹ We attempted to quantify this by calculating the genomic
333 inflation factor lambda (λ GC). A total of 35 single-nucleotide variants were selected using a previously
334 described approach (see Supplementary Table 7 and ¹⁸). Case-control comparisons were then made
335 for each of these 35 λ GC markers using Firth regression analysis. The resulting test statistics were
336 used to calculate the median value of λ GC.¹⁸

337

338 *Albinism-related genotypes*: To reduce the likelihood of obtaining spurious results due to the impact of
339 albinism-related variants other than the two studied changes (*TYR*:c.1205G>A and
340 *OCA2*:c.1327G>A), we excluded individuals who carried genotypes consistent with a molecular
341 diagnosis of albinism. This included study subjects with:

- 342 • homozygous pathogenic or likely pathogenic HGMD-listed variants in autosomal albinism-related
343 genes (*TYR*, *OCA2*, *TYRP1*, *SLC45A2*, *SLC24A5*, *C10ORF11*, *HPS 1 to 10*, *LYST*, *SLC38A8*),
- 344 • presumed biallelic pathogenic or likely pathogenic HGMD-listed variants in autosomal albinism-
345 related genes (*TYR*, *OCA2*, *TYRP1*, *SLC45A2*, *SLC24A5*, *C10ORF11*, *HPS 1 to 10*, *LYST*,
346 *SLC38A8*),
- 347 • hemizygous pathogenic or likely pathogenic HGMD-listed variants in *GPR143* or *FRMD7*,
- 348 • the *TYR* c.[-301C;575C>A;1205G>A] or *TYR* c.[-301C;575C;1205G>A] albinism-related
349 haplotype¹⁹ in homozygous state
- 350 • the *TYR* c.[-301C;575C>A;1205G>A] or *TYR* c.[-301C;575C;1205G>A] albinism-related
351 haplotype in heterozygous state plus a heterozygous pathogenic or likely pathogenic variant in
352 *TYR*.

353

354 We also excluded from our analysis individuals who were found to carry pathogenic or likely
355 pathogenic variants in the *TYR* or *OCA2* gene (in heterozygous state). Small scale genetic changes
356 (with the exception of *TYR*:c.1205G>A and *OCA2*:c.1327G>A), copy number and structural variants
357 were factored in.

358

359 *Common albinism-associated alleles:* The effect of one of the studied changes (*TYR* c.1205G>A) has
360 been previously shown to be modified by the following two variants^{19-21,25,34-36} which have been added
361 as a covariate to the regression model:

- 362 • *TYR* c.-301C>T [rs4547091], located in the *TYR* promoter; the derived, non-ancestral allele c.-
363 301C (or c.-301=) has a MAF of ~60% in non-Finnish European (NFE) populations in the Genome
364 Aggregation Database (gnomAD v2.1.1)³³;
- 365 • *TYR* c.575C>A (p.Ser192Tyr) [rs1042602], which has a MAF of ~36% in gnomAD NFE
366 populations.

367 It is highlighted that the *TYR* c.-301= and the *TYR* c.575C>A (p.Ser192Tyr) alleles are frequently
368 found in linkage disequilibrium so the presence of the latter would, in most cases, suggest the
369 presence of the former on the same haplotype.

370

371 *Case-control comparisons between TYR/OCA2 genotype groups:* Our primary analysis focused on
372 performing case-control comparisons between groups of genotypes that include different alleles at
373 positions *TYR*:c.1205 and *OCA2*:c.1327. These groups were:

- 374 • group A (reference group): homozygous for *TYR*:c.1205= and *OCA2*:c.1327=
- 375 • group B (single *TYR* heterozygote group): heterozygous for *TYR*:c.1205G>A and homozygous for
376 *OCA2*:c.1327=.
- 377 • group C (single *OCA2* heterozygote group): homozygous for *TYR*:c.1205G= and heterozygous for
378 *OCA2*:c.1327G>A.
- 379 • group D (dual heterozygote group): heterozygous for the *TYR*:c.1205G>A and *OCA2*:c.1327G>A
380 variant combination.

381 Analyses were also conducted in individuals who were found to be homozygous for *TYR*:c.1205G>A
382 (but are considered unsolved, *i.e.* they do not carry the *TYR* c.575C>A or the *TYR* c.-301= variant in
383 the homozygous state); these were split into two groups:

- 384 • *group E*: homozygous for *TYR*:c.1205G>A and *OCA2*:c.1327=;
- 385 • *group F*: homozygous for *TYR*:c.1205G>A and heterozygous for *OCA2*:c.1327G>A

386

387 Group A was used as the reference group to which all other groups were compared using Firth
388 regression analysis (*i.e.* the odds ratio for this group was fixed at 1).

389

390 The primary analysis focused on a mixed case cohort (including 174 probands from the University
391 Hospital of Bordeaux cohort and 31 cases from the Genomics England 100,000 Genomes Project
392 dataset) and a control cohort from the Genomics England 100,000 Genomes Project dataset (20,350
393 unrelated individuals) (Fig.2; Supplementary Fig.1a; Supplementary Table 2). A secondary analysis
394 focusing only on individuals from the Genomics England 100,000 Genomes Project dataset (31
395 cases, 20,350 controls) was also undertaken (Supplementary Fig.1b; Supplementary Table 8).

396

397

398 **Replication of findings in the UK Biobank cohort**

399 The effect of dual heterozygosity for *TYR*:c.1205G>A and *OCA2*:c.1327G>A was studied in the UK
400 Biobank. UK Biobank is a biomedical resource containing in-depth genetic and health information
401 from >500,000 individuals from across the UK.⁴⁰ A subset of UK Biobank volunteers underwent
402 enhanced phenotyping including visual acuity testing (131,985 individuals) and imaging of the central
403 retina (84,748 individuals)⁵⁵; the latter was obtained using optical coherence tomography (OCT), a
404 non-invasive imaging test that rapidly generates cross-sectional retinal scans at micrometre-
405 resolution.^{56,57} All UK Biobank volunteers whose data were analysed as part of this study were
406 imaged using the 3D OCT-1000 Mark II device (Topcon, Japan); the relevant methodology has been
407 previously described.⁵⁵ Notably, the diagnosis of albinism has been assigned to 39 UK Biobank
408 participants (ICD-10 term “Albinism” [E70.3] in data field 41270 or resource 591) (Supplementary
409 Table 10).

410

411 Aiming to assess the robustness of the results in the combined University Hospital of Bordeaux and
412 Genomics England 100,000 Genomes Project dataset, we performed case-control analyses in UK
413 Biobank volunteers. We focused on individuals who were estimated by principal component analysis
414 to have European-like ancestries (data field 22006). First, genotyping array data were used to obtain
415 genotypes for the *TYR*:c.1205G>A variant and *OCA2*:c.1327G>A variant (data field 22418 including
416 information from the Applied Biosystems UK Biobank Axiom Array containing 825,927 markers). Only
417 individuals reliably genotyped at both sites were retained. Aiming to reduce the likelihood of obtaining
418 spurious signals due to the presence of albinism-related variants other than the two studied changes
419 (*TYR*:c.1205G>A and *OCA2*:c.1327G>A), we excluded UK Biobank participants whose genotyping

420 array data (data field 22418) suggested that they carried an HGMD-listed variant in an albinism-
421 related gene (Supplementary Data 4).
422
423 We used Firth logistic regression to perform case-control comparisons between genotype groups A-D.
424 Sex and the number of common albinism-associated alleles were used as covariates (Fig.3a;
425 Supplementary Fig.2; Supplementary Table 3).
426
427 Given that reduced visual acuity and increased central retinal thickness (due to underdevelopment of
428 the fovea) are two hallmark features of albinism we investigated the impact of selected *TYR/OCA2*
429 variant combinations on these two quantitative traits. Aiming to reduce the likelihood of obtaining
430 spurious signals due to the presence/impact of ophthalmic conditions/features not related to albinism,
431 we excluded all UK Biobank volunteers that did not have the ICD-10 term “Albinism” [E70.3] and were
432 assigned an ophthalmology-related ICD-10 code (“Chapter VII Diseases of the eye and adnexa”).
433
434 We first obtained data on the left LogMAR visual acuity for UK Biobank volunteers (data field 5201,
435 “instance 0” datasets). These visual acuity measurements were then used to compare visual
436 performance between groups of volunteers with selected *TYR/OCA2* genotype combinations
437 (genotype groups A-D) (Supplementary Fig.3). As the obtained distributions deviated from normality,
438 the Kruskal-Wallis test was used. Pair-wise comparisons were performed and the p-values were
439 adjusted using the Benjamini-Hochberg method (Fig.3b; Supplementary Table 4). Additional analyses
440 using a linear regression approach were also conducted; sex and the number of common albinism-
441 associated alleles were included as covariates (Supplementary Table 5).
442
443 We then obtained central retinal thickness measurements from UK Biobank OCT images using the
444 “macular thickness at the central subfield” data field (27802; defined as the average distance between
445 the hyperreflective bands corresponding to the RPE and the internal limiting membrane (ILM), across
446 the central 1 mm diameter circle of the ETDRS grid) for UK Biobank volunteers.⁵⁸ The obtained
447 measurements were subsequently used to compare central retinal thickness between groups of UK
448 Biobank volunteers with selected *TYR/OCA2* genotype combinations (groups A-D). As some of the
449 obtained distributions deviated from normality, the Kruskal-Wallis test was used. Pair-wise
450 comparisons were performed and the p-values were adjusted using the Benjamini-Hochberg method
451 (Fig.3c; Supplementary Table 4). Additional analyses using a linear regression approach were also

452 conducted; sex and the number of common albinism-associated alleles were included as covariates
453 (Supplementary Table 6).

454

455 It is noted that we opted to perform all UK Biobank analyses on left eye data. This is because, as per
456 study protocol⁵⁵, the left eye was tested after the right eye, potentially making the measurements from
457 the left side less prone to artifacts (as the participants were more familiar with the test).

458

459

460 **Additional analysis in the University Hospital of Bordeaux albinism cohort**

461 Further analyses were undertaken using only data from individuals in the University Hospital of
462 Bordeaux albinism cohort. After excluding study subjects who did not report having European-like
463 ancestries, the cohort was split into cases with and cases without a molecular diagnosis of albinism
464 (*i.e.* “solved” and “unsolved”). Individuals without a molecular diagnosis who carried heterozygous
465 pathogenic or likely pathogenic variants in the *TYR* or *OCA2* gene (with the exception of the two
466 studied changes *TYR*:c.1205G>A and *OCA2*:c.1327G>A) were then removed from the unsolved
467 group. The patterns observed in genotype groups A-D were then assessed using both contingency
468 table methods and Firth regression analyses (Supplementary Table 9).

469

470

471 **Ethics approval**

472 Informed consent was obtained from all participants or their parents in the case of minors. The study
473 of individuals from the University Hospital of Bordeaux albinism cohort has been approved by the
474 relevant local ethics committee (Comité de Protection des Personnes Sud-Ouest et Outre Mer III,
475 Bordeaux, France). The informed consent process for the Genomics England 100,000 Genomes
476 Project has been approved by the National Research Ethics Service Research Ethics Committee for
477 East of England – Cambridge South Research Ethics Committee. The UK Biobank has received
478 approval from the National Information Governance Board for Health and Social Care and the
479 National Health Service North West Centre for Research Ethics Committee (Ref: 11/NW/0382). All
480 investigations were conducted in accordance with the tenets of the Declaration of Helsinki.

481

482 **DATA AVAILABILITY**

483

484 The Genomics England 100,000 Genomes Project dataset is available under
485 restricted access through a procedure described at
486 [https://www.genomicsengland.co.uk/about-gecip/for-gecip-members/data-and-data-](https://www.genomicsengland.co.uk/about-gecip/for-gecip-members/data-and-data-access)
487 [access](https://www.genomicsengland.co.uk/about-gecip/for-gecip-members/data-and-data-access). The UK Biobank dataset is available under restricted access through a
488 procedure described at <http://www.ukbiobank.ac.uk/using-the-resource/>. All other
489 data supporting the findings of this study are available within the article (including its
490 Supplementary Information files).

491

492

493 **CODE AVAILABILITY**

494

495 The scripts used to analyse the datasets included in this study are available
496 at <https://github.com/davidjohngreen/tyr-oca2>.

497

498

499 **REFERENCES**

500

- 501 1. Boycott, K.M. *et al.* A diagnosis for all rare genetic diseases: The horizon and the next
502 frontiers. *Cell*. **177**, 32-37 (2019). doi: 10.1016/j.cell.2019.02.040.
- 503 2. Splinter, K. *et al.* Effect of genetic diagnosis on patients with previously undiagnosed disease.
504 *N Engl J Med*. **379**, 2131-2139 (2018). doi: 10.1056/NEJMoa1714458.
- 505 3. Posey, J.E. *et al.* Insights into genetics, human biology and disease gleaned from family
506 based genomic studies. *Genet Med*. **21**, 798-812 (2019). doi: 10.1038/s41436-018-0408-7.
- 507 4. Zurek, B. *et al.* Solve-RD: systematic pan-European data sharing and collaborative analysis
508 to solve rare diseases. *Eur J Hum Genet*. **29**, 1325-1331 (2021). doi: 10.1038/s41431-021-
509 00859-0
- 510 5. 100,000 Genomes Project Pilot Investigators. 100,000 Genomes Pilot on rare-disease
511 diagnosis in health care - Preliminary report. *N Engl J Med*. **385**, 1868-1880 (2021). doi:
512 10.1056/NEJMoa2035790.
- 513 6. Boycott, K.M. *et al.* Care4Rare Canada: Outcomes from a decade of network science for rare
514 disease gene discovery. *Am J Hum Genet*. **109**, 1947-1959 (2022). doi:
515 10.1016/j.ajhg.2022.10.002.
- 516 7. Schäffer, A.A. Digenic inheritance in medical genetics. *J Med Genet*. **50**, 641-652 (2013). doi:
517 10.1136/jmedgenet-2013-101713.
- 518 8. Katsanis, N. The continuum of causality in human genetic disorders. *Genome Biol*. **17**, 233
519 (2016). doi: 10.1186/s13059-016-1107-9.
- 520 9. Deltas C. Digenic inheritance and genetic modifiers. *Clin Genet*. **93**, 429-438 (2018). doi:
521 10.1111/cge.13150.
- 522 10. Nachtegaal, C. *et al.* Scaling up oligogenic diseases research with OLIDA: the Oligogenic
523 Diseases Database. *Database (Oxford)*. **2022**, baac023 (2022). doi:
524 10.1093/database/baac023.
- 525 11. Burkard, M. *et al.* Accessory heterozygous mutations in cone photoreceptor CNGA3
526 exacerbate CNG channel-associated retinopathy. *J Clin Invest*. **128**, 5663-5675 (2018). doi:
527 10.1172/JCI96098
- 528 12. Cooper, D.N., Krawczak, M., Polychronakos, C., Tyler-Smith, C. & Kehrer-Sawatzki, H.
529 Where genotype is not predictive of phenotype: towards an understanding of the molecular
530 basis of reduced penetrance in human inherited disease. *Hum Genet*. **132**, 1077-1130 (2013).
531 doi: 10.1007/s00439-013-1331-2.
- 532 13. Kousi, M. & Katsanis, N. Genetic modifiers and oligogenic inheritance. *Cold Spring Harb*
533 *Perspect Med*. **5**, a017145 (2015). doi: 10.1101/cshperspect.a017145.
- 534 14. Costanzo, M. *et al.* Global genetic networks and the genotype-to-phenotype relationship. *Cell*.
535 **177**, 85-100 (2019). doi: 10.1016/j.cell.2019.01.033.
- 536 15. Mukherjee, S. *et al.* Identifying digenic disease genes via machine learning in the
537 Undiagnosed Diseases Network. *Am J Hum Genet*. **108**, 1946-1963 (2021). doi:
538 10.1016/j.ajhg.2021.08.010.
- 539 16. Papadimitriou, S. *et al.* Predicting disease-causing variant combinations. *Proc Natl Acad Sci*
540 *U S A*. **116**:11878-11887 (2019). doi: 10.1073/pnas.1815601116.
- 541 17. Brehm, A. *et al.* Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS
542 patients promote type I IFN production. *J Clin Invest*. **125**, 4196-4211 (2015). doi:
543 10.1172/JCI81260.
- 544 18. Bakker, R. *et al.* The retinal pigmentation pathway in human albinism: Not so black and white.
545 *Prog Retin Eye Res*. **91**, 101091 (2022). doi: 10.1016/j.preteyeres.2022.101091.
- 546 19. Michaud, V. *et al.* The contribution of common regulatory and protein-coding TYR variants to
547 the genetic architecture of albinism. *Nat Commun*. **13**, 3939 (2022). doi: 10.1038/s41467-022-
548 31392-3.
- 549 20. Campbell, P. *et al.* Clinical and genetic variability in children with partial albinism. *Sci Rep*. **9**,
550 16576 (2019). doi: 10.1038/s41598-019-51768-8.
- 551 21. Monfermé, S. *et al.* Mild form of oculocutaneous albinism type 1: phenotypic analysis of
552 compound heterozygous patients with the R402Q variant of the TYR gene. *Br J Ophthalmol*.
553 **103**, 1239-1247 (2019). doi: 10.1136/bjophthalmol-2018-312729
- 554 22. Lasseaux, E. *et al.* Molecular characterization of a series of 990 index patients with albinism.
555 *Pigment Cell Melanoma Res*. **31**, 466-474 (2018). doi: 10.1111/pcmr.12688.
- 556 23. Caulfield, M. *et al.* The National Genomic Research Library.
557 <https://doi.org/10.6084/m9.figshare.4530893.v7> (2017).

- 558 24. Okazaki, A. & Ott, J. Machine learning approaches to explore digenic inheritance. *Trends*
559 *Genet.* **38**, 1013-1018 (2022). doi: 10.1016/j.tig.2022.04.009.
- 560 25. Jagirdar, K. *et al.* Molecular analysis of common polymorphisms within the human tyrosinase
561 locus and genetic association with pigmentation traits. *Pigment Cell Melanoma Res.* **27**, 552-
562 564 (2014). doi: 10.1111/pcmr.12253.
- 563 26. Dolinska, M.B. *et al.* Oculocutaneous albinism type 1: link between mutations, tyrosinase
564 conformational stability, and enzymatic activity. *Pigment Cell Melanoma Res.* **30**, 41-52
565 (2017). doi: 10.1111/pcmr.12546.
- 566 27. Sviderskaya, E.V. *et al.* Complementation of hypopigmentation in p-mutant (pink-eyed
567 dilution) mouse melanocytes by normal human P cDNA, and defective complementation by
568 OCA2 mutant sequences. *J Invest Dermatol.* **108**, 30-34 (1997). doi: 10.1111/1523-
569 1747.ep12285621
- 570 28. Bellono, N.W., Escobar, I.E., Lefkovith, A.J., Marks, M.S. & Oancea, E. An intracellular anion
571 channel critical for pigmentation. *Elife.* **3**, e04543 (2014). doi: 10.7554/eLife.04543.
- 572 29. Bellono, N.W., Escobar, I.E. & Oancea, E. A melanosomal two-pore sodium channel
573 regulates pigmentation. *Sci Rep.* **6**, 26570 (2016). doi: 10.1038/srep26570.
- 574 30. Pavan W.J. & Sturm, R.A. The genetics of human skin and hair pigmentation. *Annu Rev*
575 *Genomics Hum Genet.* **20**, 41-72 (2019). doi: 10.1146/annurev-genom-083118-015230.
- 576 31. Landrum, M.J. *et al.* ClinVar: improving access to variant interpretations and supporting
577 evidence. *Nucleic Acids Res.* **46**, D1062-D1067 (2018). doi: 10.1093/nar/gkx1153.
578 [accessions VCV000003779.25 & VCV000000955.52].
- 579 32. Buniello, A. *et al.* The NHGRI-EBI GWAS Catalog of published genome-wide association
580 studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res.* **47**, D1005-D1012
581 (2019). doi: 10.1093/nar/gky1120. [entries for rs1126809 and rs74653330]
- 582 33. Karczewski, K.J. *et al.* The mutational constraint spectrum quantified from variation in
583 141,456 humans. *Nature.* **581**, 434-443 (2020). doi: 10.1038/s41586-020-2308-7.
584 [entries for 11-89017961-G-A (GRCh37) and 15-28228553-C-T (GRCh37)]
- 585 34. Loftus, S.K. *et al.* Haplotype-based analysis resolves missing heritability in oculocutaneous
586 albinism type 1B. *Am J Hum Genet.* **S0002-9297**, 00169-6 (2023). doi:
587 10.1016/j.ajhg.2023.05.012.
- 588 35. Lin, S., *et al.* Evidence that the Ser192Tyr/Arg402Gln in *cis* Tyrosinase gene haplotype is a
589 disease-causing allele in oculocutaneous albinism type 1B (OCA1B). *NPJ Genom Med.* **7**, 2
590 (2022). doi: 10.1038/s41525-021-00275-9.
- 591 36. Grønskov, K. *et al.* A pathogenic haplotype, common in Europeans, causes autosomal
592 recessive albinism and uncovers missing heritability in OCA1. *Sci Rep.* **9**, 645 (2019). doi:
593 10.1038/s41598-018-37272-5.
- 594 37. Heinze, G. & Schemper, M. A solution to the problem of separation in logistic regression. *Stat*
595 *Med.* **21**, 2409-19 (2002). doi: 10.1002/sim.1047.
- 596 38. Firth, D. Bias reduction of maximum likelihood estimates. *Biometrika.* **80**, 27-38 (1993). doi:
597 10.1093/biomet/80.1.27
- 598 39. Marchini, J., Cardon, L.R., Phillips, M.S. & Donnelly, P. The effects of human population
599 structure on large genetic association studies. *Nat Genet.* **36**, 512-517 (2004). doi:
600 10.1038/ng1337
- 601 40. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature.*
602 **562**, 203-209 (2018). doi: 10.1038/s41586-018-0579-z.
- 603 41. Masson, E. *et al.* Expanding ACMG variant classification guidelines into a general framework.
604 *Hum Genomics.* **16**, 31 (2022). doi: 10.1186/s40246-022-00407-x.
- 605 42. Richards, S. *et al.* Standards and guidelines for the interpretation of sequence variants: a joint
606 consensus recommendation of the American College of Medical Genetics and Genomics and
607 the Association for Molecular Pathology. *Genet Med.* **17**, 405-424 (2015). doi:
608 10.1038/gim.2015.30.
- 609 43. Freedman, M.L. *et al.* Assessing the impact of population stratification on genetic association
610 studies. *Nat Genet.* **36**, 388-93 (2004). doi: 10.1038/ng1333.
- 611 44. Devlin, B. & Roeder, K. Genomic control for association studies. *Biometrics.* **55**, 997-1004
612 (1999). doi: 10.1111/j.0006-341x.1999.00997.x
- 613 45. Dadd, T., Weale, M.E. & Lewis, C.M. A critical evaluation of genomic control methods for
614 genetic association studies. *Genet Epidemiol.* **33**, 290-298 (2009). doi: 10.1002/gepi.20379.
- 615 46. Turnbull, C. *et al.* The 100,000 Genomes Project: bringing whole genome sequencing to the
616 NHS. *BMJ* **361**, 1687 (2018). doi: 10.1136/bmj.k1687

- 617 47. Köhler, S. *et al.* The Human Phenotype Ontology in 2021. *Nucleic Acids Res.* **49**, D1207–
618 D1217 (2021). doi: 10.1093/nar/gkaa1043
- 619 48. Raczy, C. *et al.* Isaac: ultra-fast whole-genome secondary analysis on Illumina sequencing
620 platforms. *Bioinformatics* **29**, 2041–2043 (2013). doi: 10.1093/bioinformatics/btt314.
- 621 49. Chen, X., *et al.* Manta: rapid detection of structural variants and indels for germline and
622 cancer sequencing applications. *Bioinformatics* **32**, 1220-1222 (2016). doi:
623 10.1093/bioinformatics/btv710.
- 624 50. Roller, E., Ivakhno, S., Lee, S., Royce, T. & Tanner, S. Canvas: versatile and scalable
625 detection of copy number variants. *Bioinformatics* **32**, 2375-2377 (2016). doi:
626 10.1093/bioinformatics/btw163.
- 627 51. Tan, A., Abecasis, G.R. & Kang, H.M. Unified representation of genetic variants.
628 *Bioinformatics* **31**, 2202–2204 (2015). doi: 10.1093/bioinformatics/btv112
- 629 52. Danecek, P. *et al.* Twelve years of SAMtools and BCFtools. *Gigascience* **10**, giab008 (2021).
- 630 53. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol.* **17**, (2016). doi:
631 10.1186/s13059-016-0974-4
- 632 54. Stenson, P.D. *et al.* The Human Gene Mutation Database (HGMD®): optimizing its use in a
633 clinical diagnostic or research setting. *Hum Genet.* **139**, 1197-1207 (2020). doi:
634 10.1007/s00439-020-02199-3.
- 635 55. Chua, S.Y.L., *et al.* Cohort profile: design and methods in the eye and vision consortium of
636 UK Biobank. *BMJ Open* **9**, e025077 (2019).
- 637 56. Bouma, B.E. *et al.* Optical coherence tomography. *Nat Rev Methods Primers.* **2**, 79 (2022).
638 doi: 10.1038/s43586-022-00162-2.
- 639 57. Drexler, W. & Fujimoto, J.G. State-of-the-art retinal optical coherence tomography. *Prog Retin*
640 *Eye Res.* **27**, 45–88 (2008). doi: 10.1016/j.preteyeres.2007.07.005
- 641 58. Currant, H. *et al.* Genetic variation affects morphological retinal phenotypes extracted from
642 UK Biobank optical coherence tomography images. *PLoS Genet.* **17**, e1009497 (2021). doi:
643 10.1371/journal.pgen.1009497
644

645

646

647 **ACKNOWLEDGEMENTS**

648

649 We acknowledge the following sources of funding: the Wellcome Trust

650 (224643/Z/21/Z, Clinical Research Career Development Fellowship to P.I.S.;

651 200990/Z/16/Z, Transforming Genetic Medicine Initiative to G.C.B.); the UK National

652 Institute for Health Research (NIHR) Clinical Lecturer Programme (CL-2017-06-001

653 to P.I.S.); Retina UK and Fight for Sight (GR586, RP Genome Project - UK Inherited

654 Retinal Disease Consortium to G.C.B.); Christopher Green (D.J.G.); the French

655 Albinism Association (Genespoir) and the French National Research Agency

656 (Agence Nationale de la Recherche; ANR-21-CE17-0041-01 to B.A.).

657

658 The UK Biobank Eye and Vision Consortium is supported by funding from the NIHR

659 Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of

660 Ophthalmology, the Alcon Foundation and the Desmond Foundation. The complete
661 list of members of this Consortium can be found in the Supplementary Information
662
663 This research was made possible through access to the data and findings generated
664 by the 100,000 Genomes Project. The 100,000 Genomes Project is managed by
665 Genomics England Limited (a wholly owned company of the Department of Health
666 and Social Care). The 100,000 Genomes Project is funded by the NIHR and NHS
667 England. The Wellcome Trust, Cancer Research UK and the Medical Research
668 Council have also funded research infrastructure. The 100,000 Genomes Project
669 uses data provided by patients and collected by the National Health Service (NHS)
670 as part of their care and support. We acknowledge the contribution of the Genomics
671 England Research Consortium to the 100,000 Genomes Project. The complete list of
672 members of this Consortium can be found in the Supplementary Information.
673
674 Lastly, we acknowledge the help of Cécile Courdier at the University Hospital of
675 Bordeaux Molecular Genetics Laboratory, Sophie Javerzat at the University of
676 Bordeaux, Dave Gerrard at the University of Manchester, and Claire Hardcastle,
677 Chris Campbell, Steph Barton and Simon Ramsden at the North West of England
678 Genomic Laboratory Hub.

679 **AUTHOR CONTRIBUTIONS STATEMENT**

680

681 P.I.S. conceived and designed the experiments. The UK Biobank Eye and Vision

682 Consortium, T.F., E.B., B.A., G.C.B. and P.I.S provided datasets and analytical tools.

683 D.J.G., V.M., E.L., C.P., T.F., B.A. and P.I.S. analysed the data. P.I.S. wrote the

684 manuscript with support from D.J.G. All authors critically revised and approved the

685 manuscript.

686

687 G.C.B. and B.A. contributed equally to this work.

688

689

690

691 **COMPETING INTERESTS STATEMENT**

692

693 E.B. is a paid consultant and equity holder of Oxford Nanopore, a paid consultant to

694 Dovetail, and a non-executive director of Genomics England, a limited company

695 wholly owned by the UK Department of Health and Social Care. All other authors

696 declare no competing interests.

697

698

699 **UK Biobank Eye and Vision Consortium**

700

701 Graeme C. Black^{1,5}, Panagiotis I. Sergouniotis^{1,4,5,6}

702

703 ¹ Division of Evolution, Infection and Genomics, School of Biological Sciences,

704 Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

705

706 ⁴ European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-

707 EBI), Wellcome Genome Campus, Cambridge, UK.

708

709 ⁵ Manchester Centre for Genomic Medicine, Saint Mary's Hospital, Manchester

710 University NHS Foundation Trust, Manchester, UK.

711

712 ⁶ Manchester Royal Eye Hospital, Manchester University NHS Foundation Trust,


713 Manchester, UK.

714

715 A full list of members appears in the Supplementary Information.

Bordeaux
albinism
cohort

100K_GP
albinism
cohort




Inclusion criteria:

- European ancestries
- Unsolved following genetic analysis for albinism
- No pathogenic or likely pathogenic variants in *TYR* or *OCA2* (except for *TYR* c.1205G>A and *OCA2* c.1327G>A)

controls



cases




heterozygous
TYR c.1205G>A

heterozygous
OCA2 c.1327G>A

case-control analysis
using Firth logistic
regression

covariates:

- sex
- common albinism-associated *TYR* alleles (*TYR* c.-301C and *TYR* c.575C>A)



validation:

- analysis repeated in cases and controls from the 100K_GP only
- analysis repeated and expanded in an independent cohort (UK Biobank)

genotype

<i>TYR:</i> c.1205G>A (p.Arg402Gln)	<i>OCA2:</i> c.1327G>A (p.Val443Ile)	group	number of proband (cases / controls)
GG	GG	A	103 / 10,369
AG	GG	B	71 / 8,011
GG	AG	C	7 / 158
AG	AG	D	10 / 128

**probability of receiving
a diagnosis of
albinism (odds ratio, log₁₀)**

